Neuropharmacology employs knowledge derived from neuroscience research to determine how psychotherapeutic and psychotomimetic drugs and neurotoxins act in the CNS and the neurochemical substrates that mediate their activity. The proposed training program combines the talents of neuroscientists and trainee recruiting resources from three ongoing programs [The Department of Pharmacology The College of Medicine, The Division of Pharmacology, The College of Pharmacy and The Neuroscience Program an intercollegiate program]. The training program will provide the next generation of scientists with the intellectual and technical skills needed to continue with the important task of unmasking the mechanism of action of psychotherapeutic drugs, developing new therapeutic agents and understanding the cause of mental illness. Two predoctoral trainees are requested for the first year and four each year thereafter for a total of five years of funding. One postdoctoral trainee is requested for the first year and two for the following years. The predoctoral trainees will be eligible for the program after becoming a candidate for a Ph.D. i.e., after completing the General Examination. It is anticipated that trainees will complete their thesis requirement in two years. Postdoctoral trainees are anticipated to complete training in two years. The faculty are a cohesive group of funded neuroscientists with contemporary and traditional neuropharmacological research experiences including molecular biotechnology, neurochemistry, cell culture, patch-clamp recording and image analysis capabilities. The training program takes advantage of all of the research, teaching and recruiting resources of three major programs at The Ohio State University.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Institutional National Research Service Award (T32)
Project #
5T32MH019936-05
Application #
2890229
Study Section
Neuropharmacology and Neurochemistry Review Committee (NPNC)
Program Officer
Goldschmidts, Walter L
Project Start
1995-07-01
Project End
2001-06-30
Budget Start
1999-07-01
Budget End
2001-06-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Ohio State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fadel, J; Sarter, M; Bruno, J P (2001) Basal forebrain glutamatergic modulation of cortical acetylcholine release. Synapse 39:201-12
Fadel, J; Sarter, M; Bruno, J P (1999) Age-related attenuation of stimulated cortical acetylcholine release in basal forebrain-lesioned rats. Neuroscience 90:793-802
Miner, L A; Sarter, M (1999) Intra-accumbens infusions of antisense oligodeoxynucleotides to one isoform of glutamic acid decarboxylase mRNA, GAD65, but not to GAD67 mRNA, impairs sustained attention performance in the rat. Brain Res Cogn Brain Res 7:269-83
Miner, L A; Ostrander, M; Sarter, M (1997) Effects of ibotenic acid-induced loss of neurons in the medial prefrontal cortex of rats on behavioral vigilance: evidence for executive dysfunction. J Psychopharmacol 11:169-78
Vogelsberg, V; Neff, N H; Hadjiconstantinou, M (1997) Cyclic AMP-mediated enhancement of high-affinity choline transport and acetylcholine synthesis in brain. J Neurochem 68:1062-70
Vogelsberg, V; Fong, T G; Neff, N H et al. (1997) Cholinergic deficits in aged rat spinal cord: restoration by GM1 ganglioside. Brain Res 761:250-6
Fong, T G; Neff, N H; Hadjiconstantinou, M (1997) GM1 ganglioside improves spatial learning and memory of aged rats. Behav Brain Res 85:203-11
Copeland, B J; Vogelsberg, V; Neff, N H et al. (1996) Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J Pharmacol Exp Ther 277:1527-32